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Background: This paper analyses the direct medical costs of type 2 diabetes and its complications in Switzerland. Methods:
Individual healthcare resource consumption related to type 2 diabetes and its complications was determined retrospectively in
1479 non-incident and non-dying patients over 12 months (1998–1999). Literature-derived attributable risks were used to
correct for non-diabetes related macrovascular disease. Results: A total of 111 primary care physicians from 19 cantons
throughout Switzerland participated. Their diabetic patients on average had 10.3 consultations per year related to this disease
(95% CI: 10.0–10.7). Patients spent on average 2.7 days (95% CI: 2.2–3.3) per year in hospital due to diabetes and
diabetes-related complications. Mean annual type 2 diabetes-related direct medical costs per patient amounted to CHF 3,508
/ € 2,323 (95% CI: CHF 3,140–3,876 / € 2,080–2,567). They were particularly high in patients with insulin treatment or
with complications. After application of attributable risks and a correction for the use of adjuvant materials, costs were CHF
3,324 / € 2,201. Assuming 250,000 patients with type 2 diabetes in Switzerland leads to an estimate of CHF 0.88 billion
spent for this disease and its complications in 1998. This represents a share of about 2.2% of the country’s total healthcare
expenditures. Conclusion: These findings demonstrate the high economic importance of type 2 diabetes and its complications
in Switzerland.
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Type 2 diabetes mellitus is one of the great challenges in public
health. The number of people suffering from diabetes worldwide
was estimated by the WHO at 135 million in 1995. This figure
was projected to more than double by the year 2025, the reasons
being ageing of the population, unhealthy diet, a sedentary
lifestyle and subsequent obesity.1,2 In relative terms about 2.1%
of the world’s population have diabetes, a number which is
expected to increase to 3.0% by 2010.2 Type 2 diabetes accounts
for approximately 90% of all cases of diabetes in the world.
Besides its increasing health impact the economic burden of
diabetes is enormous. A study conducted by the World Bank
found that of 1,362 million DALYs lost to all illnesses in 1990,
7.97 million DALYs (0.59%) were lost to diabetes.3 In the
USA diabetes is known to be a major source of morbidity,
mortality and economic expense.4,5 US direct medical and
indirect expenditures attributable to diabetes in 1997 were
estimated at $ 98.2 billion.5
No empirical studies are available of the healthcare costs of
diabetes in Switzerland, apart from a cost-effectiveness analysis
of different management strategies for type 1 diabetes and two
modelling studies on type 2 diabetes.6–8 Data from other
European countries cannot be assumed to be a priori applicable
to Switzerland due to differing healthcare and pricing systems.
This is even more true for the results of a relatively large number
of US studies addressing this subject.
The aim of this study was to determine the direct medical costs
of type 2 diabetes mellitus and its complications in Switzerland.
A ‘bottom-up’ approach was used, as there are only very few
aggregate healthcare data available in Switzerland. Calculations
were based on the costs of the individual units of service
performed.
METHODS
Physician and patient sample
From the Swiss Medical Association’s 1998 list, 3,100 primary
care physicians were randomly selected and invited to participate
if they treated 10 or more diabetes patients. A total of 111 general
practitioners and non-subspecialized internists from all over
Switzerland provided information extracted from their medical
charts. They were asked to include all patients with type 2
diabetes who attended their office during the last 12 months, in
order to minimize possible selection biases. Classification of
diabetes was left to their judgement and not influenced by the
study group.
Data were collected between June 1998 and September 1999.
Patients who were newly diagnosed or died within the reviewed
time period were excluded to avoid distortions by observations
with extreme values. The exclusion of newly diagnosed cases
implies a strictly prevalence-based approach.
Patient data and healthcare resource utilization
Diabetes-related healthcare utilization and cost-inducing events
were recorded for 12 months retrospectively. Collection of data
included gender, age, age at diagnosis, type of treatment, the
presence of microvascular complications (neuropathy, nephro-
pathy, retinopathy), macrovascular complications (coronary
heart disease, cerebrovascular disease, peripheral artery disease),
and related events. At the resource use level, recording com-
prised diabetes-related medication, consultations, laboratory
tests, imaging diagnostics, ambulatory procedures, hospital stays,
and home healthcare. Insurance and employment status were
also recorded, as well as the number of working days lost. The
use of adjuvant materials like glucose monitoring devices, strips
and syringes could not be assessed from the medical charts. It was
estimated, at the aggregate level, from the experience available
in a large Swiss outpatient diabetes unit.
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Clinical data
Although resource utilization was the primary interest of this
study, selected clinical data, which were felt to be important for
further analyses, were also recorded. Parameters included height,
weight, last measurements of laboratory parameters (plasma
glucose, HbA1c, total cholesterol, HDL-cholesterol, tri-
glycerides, serum creatinine, and urine albumin excretion), and
the last recorded blood pressure measurement.
Costs
To estimate the economic impact of type 2 diabetes and its
complications, direct medical costs were calculated. Prices and
charges were used as proxy measures of real costs. All ex-
penditures on the resources used were taken into account in-
dependently of the payer (patient, third-party, or state). In this
sense, a societal perspective of cost assessment was adopted.
Direct medical costs comprised expenditures for outpatient care
(consultations of general practitioners and specialists, laboratory
tests, imaging diagnostics, ambulatory surgeries, prescribed out-
patient nursing services and education by nurses), in-patient care
(hospitalizations, inpatient procedures), and medication.
Treatment costs of diabetes-related complications (neuropathy,
nephropathy, eye complications, and macroangiopathy) were
also included. Services provided by physiotherapists or dieticians
and the costs of long-time hospice care could not be assessed.
The costs of adjuvant materials were estimated at an aggregate
level. All expenditure calculations were based on 1998/1999
prices and tariff lists.
Costs of outpatient care
To estimate the costs induced by consultations of general
practitioners, the number of visits was multiplied by the
applicable consultation fees. To estimate the expenditures for
out-patient care provided by ophthalmologists, the number of
diabetes-related visits was multiplied by the sum of charges for
the typical services covered.
The number of laboratory tests performed was multiplied by the
applicable tariffs.9 The costs of imaging diagnostics (X-rays,
Doppler sonography, computer tomography and magnetic
resonance imaging), of outpatient eye surgeries, of prescribed
home care services, and of diet counsel and education by diabetes
nurses were assessed according to the same principles.10,11
Costs of in-patient care
Estimates of in-patient care costs included costs of hospitaliza-
tion and of inpatient interventions (PTCA, PTA and bypass
surgery) as well as costs of haemodialysis.
Expenditures for hospital care were estimated by multiplying the
reported number of hospital days by the average regional cost per
in-patient day spent on the general ward of a public hospital.12
Public subsidies to the hospitals were added.
Expenditures for in-patient surgical interventions were cal-
culated by multiplying the number of operations with the charges
for the respective surgery.10 The corresponding hospital days
were accounted for as indicated above. Costs of haemodialysis
were calculated from data provided by the Swiss Association for
Common Issues in Health Insurance.13
Costs of medication
All prescribed medications with a direct or indirect relation to
diabetes were recorded by name and daily dosage if taken
regularly or continuously. The yearly dosage of every medication
was calculated and finally multiplied by its unit price, using 1999
public prescription prices.14 Non-prescription-based out-of-
pocket expenses were not assessed.
Attributable risks
The cost figures resulting from the described procedure are costs
of type 2 diabetes and its complications including macrovascular
disease, but not all costs of macrovascular disease are diabetes
related. The same is true for cataract and cataract surgery.
Corrected cost figures were modelled by applying literature-
derived diabetes-attributable risks to the costs of CABG surgery
and PTCA, to the inpatient costs of patients with macrovascular
disease, to the costs of cardiovascular drugs, and to the costs of
cataract surgery.15,16 If macrovascular and microvascular disease
were present, it was assumed that only half of the hospital days
reported were due to the former. Costs of physician consultations
were not corrected, as the share of consultations due to macro-
vascular disease could not be to judged. Lipid tests were not
corrected, as they were assumed to be necessary in all type 2
diabetes patients.
Statistical analysis
Non-stratified and stratified descriptive analyses were performed
using SPSS version 10.0.
RESULTS
A total of 111 physicians from 19 cantons throughout Switzer-
land participated and provided data on a total of 1479 patients
who were currently being treated for type 2 diabetes. Two-thirds
(66%) of the patients were seen by a general practitioner, 27%
were seen by a doctor without specialization, and 7% by a
non-subspecialized internist. On average every physician re-
ported data on 13.2 patients (median 15 patients). Overall
reporting quality was good, with less than 5% missing values in
nearly all variables relevant for cost analysis.
Patient population
The 1479 patients analysed represent a sample of about 0.6% of
all Swiss patients with type 2 diabetes. Demographic data are
shown in table 1 which shows that 83% (1226) of the patients
came from the German speaking part of Switzerland, 16% (239)
from the French speaking part, and 1% (14) from the Italian
speaking part.
The following labour force participation rates were recorded:
full-time employment 26.5%, part-time employment 3.7%, self-
employed 7%, not employed 16.9%, jobless 1%, pensioners
38.6%, disability pensioners 6.2%.
Information on insurance status was available from 1041
patients. 81% of these patients had basic statutory insurance
coverage only, 19% had a supplementary insurance package.
Type of treatment was distributed as follows: no specific treat-
ment for diabetes was reported in 1.2% (17) of the patients;
dietary treatment only was reported in 14.1% (208); while 60.1%
Table 1 Demographic data of study population (N=1479)
Value 
(mean ± SD or %)
Age (years) 66 ± 12.3
Male/Female (%) 49.4 / 50.1
German/French/Italian speaking (%) 82.9 / 16.2 / 0.9
Height (cm) 167 ± 9.13
Weight (kg) 81.2 ± 16.55
BMI (m/kg2) 29.4 ± 5.46
Duration of diabetes (years) 9.2 ± 7.04
Family history of diabetes (%) 29.5
Blood glucose (mmol/l, last measurement) 8.86 ± 3.03
HbA1c (%, last measurement) 7.72 ± 1.66
Diet treatment (%) 85.8
Diabetes-related drugs prescribed (%) 93.0
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(887) had oral antidiabetic drugs. Insulin was used by 24.6%
(364), in part combined with oral antidiabetic agents.
Diabetes-related complications were present in 56% of patients
(table 2). Macrovascular complications (excluding hyper-
tension) were present in 27%. Acute myocardial infarction and
stroke affected 2.6% and 2.3% during the last year. Micro-
vascular complications were recorded in 43%, neuropathy (in-
cluding diabetic foot syndrome) in 23%, nephropathy (including
microalbuminuria and proteinuria) in 28%, and eye complica-
tions in 13%. Amputations during the last year were reported in
1.6% of cases. As many as 15% of patients were affected by both
macrovascular and microvascular complications.
Resource use
Mean annual medical resource utilization of patients with type
2 diabetes is shown in table 3. On average, patients had 10.3
diabetes-related physician consultations per year (95% CI: 10.0–
10.7). In 15.4%, there was at least one hospitalization during the
previous year which was due to diabetes or a diabetes-related
complication. On average these persons spent 17.8 days in
hospital (95% CI: 15.2–20.4), which results in a mean of 2.7 days
(95% CI: 2.2–3.3) for the whole study population. Only every
second patient had an ophtalmological control during the
observation period. Apart from blood glucose measurements,
HbA1c measurements were the most frequently performed
laboratory tests.
Costs
Important direct cost factors are summarized in table 4. Mean
annual direct medical costs of type 2 diabetes and its com-
plications amounted to CHF 3,508 (95% CI: CHF 3,140–3,876)
per year. Hospitalization costs, being the largest cost factor by
far, contributed 53% of these costs. Medication costs contributed
30%. Ambulatory costs, comprising consultations, outpatient
diagnostic and invasive procedures, and home care services by
nurses, accounted for 17%.
The cost distribution of diabetes-related medication is charac-
terized by a dominance of cardiovascular drugs over antidiabetic
agents. The shares of oral antidiabetic drugs and insulin in the
total medication costs were 24.7% and 17.3% (42% in total).
The share of cardiovascular medications and lipid-lowering drugs
was 39.4% and 9.2% (48.6% in total). Antibiotics used for the
Table 3 Annual medical resource utilisation in patients with 
type 2 diabetes (N=1479)
Frequency/patient/year
Resource Mean 95% CI
Physician visits 10.3 10.0–10.7
Ophthalmological controls 0.55 0.51–0.59
Laboratory tests 11.83 11.48–12.18
Plasma glucose 5.81 5.58–6.04
HbA1c 2.02 1.92–2.11
Serum creatinine 1.28 1.20–1.37
Cholesterol 1.05 0.99–1.11
HDL cholesterol 0.71 0.66–0.76
Triglycerides 0.80 0.74–0.85
Urine albumin (24 h) 0.17 0.13–0.20
Prescribed nurse visits 1.29 0.50–2.09
Computer tomographies 0.033 0.02–0.05
MRI 0.011 0.005–0.02
Hospitalizations 0.22 0.18–0.25
Hospital days 2.74 2.22–3.25
Peripheral dilatations 0.014 0.008–0.02
PTCA 0.0095 0.005–0.015
Table 2 Complication frequencies of study population
Frequency
Type of complication N %
Coronary heart disease 312 / 1473 21.2
Peripheral arterial insufficiency 157 / 1473 10.7
Macrovascular complications (≥1) 393 / 1473 26.7
Neuropathy 342 / 1461 23.4
Nephropathy (incl. 
microalbuminuria and proteinuria) 365 / 1315 27.8
Retinopathy 188 / 1424 13.2
Microvascular complications (≥1) 619 / 1447 42.8
Any complication 816 / 1456 56.0
Both types of complications 215 / 1443 14.9
Myocardial infarction during the
last year 39 / 1473 2.6
Stroke during the last year 34 / 1473 2.3
Amputation during the last year 23 / 1473 1.6
Table 4 Mean type 2 diabetes-related costs (direct, indirect and total) per year per patient in CHF and € (N=1479)
Mean costs 95% CI Attributable risk corrected costs
Cost category CHF € a CHF € a CHF € a 
Direct medical costs 3,508 2,323 3,140–3,876 2,080–2,567 3,004 1,990
Drug costs 1,059 701 1,010–1,108 669–734 889 589
Ambulatory costs 592 392 559–625 370–414 558 370
Consultationsb 295 195 282–308 176–191 295 195
Outpatient diagnostic proceduresc 26 17 19–34 13–23 26 17
Outpatient invasive proceduresd 98 65 73–123 48–81 65 43
Laboratory tests 172 114 166–178 110–118 172 114
Hospital care 1,856 1,229 1,509–2,203 999–1,459 1,557 1,031
a: Exchange rate: CHF 1 = € 0.6623 (11.12.2000).
b: Including outpatient nursing services.
c: X-rays, Doppler sonography, computer tomography, and magnetic resonance imaging.
d: Vitrectomy, laser therapy, and cataract extraction.
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treatment of diabetic foot syndromes accounted for 0.5% of the
total, and all other medications for 7.6%.
Table 5 shows direct medical costs stratified by treatment type
and by the presence of complications. Diet-treated patients cost
about 1.6 times more than the few untreated patients in our
sample. The costs of diet-treated patients and of patients treated
with oral antidiabetic drugs were nearly identical. Compared to
these groups, insulin-treated patients were twice as expensive.
Cost differences according to complication status were even
more distinct. Patients with at least one microvascular complica-
tion cost nearly twice as much as patients without complications.
Patients with at least one macrovascular complication (ex-
cluding hypertension) cost nearly three times as much, and
persons with both types of complications more than four times
as much. Within the group of patients with microvascular com-
plications, isolated retinopathy was associated with particularly
high costs. The same was true for isolated cerebrovascular disease
within the group of patients with macrovascular complications.
The character of these findings remained unchanged after further
stratifying by both treatment type and complication status, by
quartiles of the duration of diabetes, and by quartiles of the last
measured HbA1c value (data not shown.)
Cost correction for adjuvant materials
The utilization of glucose monitoring strips was estimated at
CHF 15 per month. Glucose monitoring devices were assumed
to be exchanged every two years. The mean costs of all other
adjuvant materials were estimated to be CHF 0.50 per day in
those using insulin. These assumptions lead to an estimate of the
costs of adjuvant materials of CHF 320 (€ 212) per year.
Cost correction by application of attributable risks
Available evidence allows for the assumption that the relative
risk of coronary heart disease in persons with diabetes is in the
range of 2.5.17–21 This corresponds to an attributable risk of 0.6.
The relative risk of stroke can be assumed to be 4, with an
attributable risk of 0.75.22–24 Studies on cataract indicated an
odds ratio of cataract surgery in persons with compared to persons
without diabetes of 1.8 to 2.5. If the rare disease assumption is
made, the corresponding relative risk can be estimated to be in
the range of 2, and the attributable risk to be in the range of
0.5.25–27 Application to the cost results of this analysis reduces
mean inpatient costs to CHF 1,557, mean costs of consultations
and outpatient services to CHF 262, mean medication costs to
CHF 889, and mean direct costs to CHF 3,004 (table 4). The
relative size of the different cost factors is hardly affected.
Applying both the attributable risk correction and the correction
for the adjuvant materials changes the primary cost estimate to
CHF 3,324 (€ 2,201).
Total healthcare expenditures for type 2 diabetes in Switzerland
Studies to determine the exact prevalence of type 2 diabetes in
Switzerland have not been published. According to an estimate
of the Swiss Diabetes Association there are 250,000 patients with
type 2 diabetes in Switzerland. Combining this number with the
cost figure of CHF 3,508 leads to an estimate of the total 1998
costs of type 2 diabetes and its complications of CHF 0.88 billion,
which represents a share of 2.2% of total healthcare expenditures
in Switzerland. If the corrected cost figure of CHF 3,324 is used,
total costs at this level are CHF 0.83 billion or 2.1% of total
healthcare expenditures in Switzerland.
DISCUSSION
Bias and cost measurement issues have to be addressed. Parti-
cipation was restricted to physicians treating a minimum of 10
persons with diabetes. At least in part, this explains the low
nominal participation rate of 3.6% of the physicians invited.
Still, it cannot be ruled out that some selection bias was intro-
duced at this level, affecting the ability to generalize the results,
but there is no obvious reason to assume a link between physician
participation and resource use. Also, some doctors could have
chosen not to include their most problematic and expensive
cases, which would have resulted in an underestimation of costs.
Nevertheless, the representativeness of our sample is supported
by the patient characteristics observed (table 1), which are well
in the range to be expected from other European studies referring
to patients with a known history of type 2 diabetes.28–30
An abstract referring to an epidemiological cross-sectional
CODE-2 substudy conducted in Germany reports, among other
data, cardiovascular complications in 43% of patients,
neuropathy in 23%, and ophthalmological complications in
11%.31 Cardiovascular complications were observed in 23% of
Table 5 Mean type 2 diabetes-related direct costs per year per patient in CHF and €, by treatment type and by complication status
Mean 95% CI Relation to mean
direct costsN CHF € a CHF € a 
Treatment group
No treatment 17 1,732 1,147 308–3,156 204–2,090 0.49
Diet only 208 2,822 1,869 1,841–3,804 1,219–2,519 0.80
Oral antidiabetics 887 2,776 1,839 2,422–3,130 1,604–2,073 0.79
Insulin treatment 364 5,779 3,827 4,729–6,839 3,132–4,529 1.65
Complication status
No complications 640 1,723 1,141 1,477–1,970 978–1,304 0.49
Microvascular 419 3,205 2,123 2,704–3,706 1,791–2,454 0.91
Nephropathyb 153 2,009 1,331 1,554–2,465 1,029–1,633 0.57
Neuropathyb 77 2,199 1,370 1,494–2,903 931–1,809 0.63
Retinopathyb 36 3,893 2,425 2,189–5,598 1,364–3,488 1.11
Macrovascular 170 5,050 3,345 3,901–6,198 2,584–4,105 1.44
Cardiovascularb 114 4,394 2,737 3,124–5,664 1,946–3,529 1.25
Cerebrovascularb 7 11,042 6,879 0–22,850 0–14,236 3.15
Peripheralb 23 3,601 2,243 1,358–5,843 846–8,869 1.03
Micro- and macrovascular 215 8,475 5,613 6,598–10,351 4,370–6,855 2.42
a: Exchange rate: CHF 1 = € 0.6623 (11.12.2000).
b: Persons with isolated occurrence of the named complication. No other complication.
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patients only, but similar shares of patients with microvascular
complications. Part of this discrepancy may arise from different
definitions, e.g. a possible inclusion of hypertension in the
definition of CHD in the CODE-2 substudy. Another part may
be due to the fact that our questionnaire explicitly referred to a
time interval of 12 months. This may have caused an under-
reporting of CHD in patients who were not affected by a CHD-
related event during the observation period.
Our method of cost measurement reflects the availability of data
in Switzerland. Many cost-of-illness studies in the field of
diabetes used ‘top-down’ approaches, particularly in the
USA.15,32 They were based on national aggregate databases and
on general population surveys of health, healthcare, disability,
and mortality. In Switzerland, only very few healthcare data are
available on an aggregate level. ‘Bottom-up’ studies are an
accepted alternative in this kind of situation, albeit they are
subjected to the risks of extrapolation if statements at the popu-
lation level are required. In general terms, they allow for more
precise cost estimates, as individual utilization patterns are
observed directly rather than estimated from aggregate data. On
the other hand they tend to be conservative, the main reason
being the near-impossibility to measure all potentially relevant
consumptions of resources.
In particular, three facts hint at a certain underestimation of the
true costs of type 2 diabetes and its complications in this study:
1) physicians may not have had a complete overview of all
resource utilizations of their diabetic patients. They may not
have learned of some consultations of specialized physicians, and
they surely did not record out-of-pocket expenses. Also,
physicians’ charts do not document all cost-inducing details of,
for example, patients’ inpatient episodes. 2) Services provided
by physiotherapists or dieticians and the costs of long-time
hospice care could not be taken into account in our calculations.
The costs of adjuvant materials such as glucose monitoring
devices and strips could only be estimated. 3) The exclusion of
incident and dying cases implies a certain underestimation of
costs and a potential limitation of the generalizability of our
results to all Swiss patients with type 2 diabetes. However, the
results of Brown et al., referring to the costs of US patients with
type 2 diabetes during the first eight years after diagnosis, support
the expectation that the underestimation induced is relatively
small.
Showing the costs of patients with different kinds of isolated
diabetic complications (table 5) is illustrative but may, to a
certain extent, be misleading. Persons with additional conditions
may have different costs with respect to the complication in
question. On the other hand, if all persons with this complication
are considered, unregarding the presence of other conditions, its
relative contribution remains again unclear.
A major point to discuss is the assessment of the costs of diabetes
complications in general. The question of the share of diabetes
is easily answered with respect to microvascular disease, but not
regarding macrovascular disease which is present in the general
population as well. Some US studies used epidemiological
population-attributable risk formulas to assess the diabetes-
related costs of macrovascular disease, but, due to the lack of large
databases, reliable attributable risk figures are difficult to
generate in Switzerland.5,33 Other studies, like CODE-2,
measured total healthcare costs of persons with type 2 diabetes,
but the resulting figures are of limited use without a control
group.1,28 Including an adequate control group would have been
beyond the scope and possibilities of this study. Therefore,
diabetes-related costs were measured, and complication costs
were included in total. In a second step, literature-derived
relative risks were used to estimate the diabetes attributable risks
(at the patient level) of macrovascular disease and cataract.15,16
Using these, corrected costs were calculated. These can be
viewed as a broad estimate of the costs of type 2 diabetes itself.
Table 6 Examples of cost of illness studies in the field of diabetes
Reference
Parameter
Rubin et al. 
19944 
American Diabetes
Association 19985 
Brown et al. 
199934 
Henrikkson et al.
199830 
Detournay et al.
199936 
Jönsson 2002
(CODE-2)28 
Country and
year of 
reference
USA, 1992 USA, 1997 USA, 8 years 
from 1988–1995
Sweden, 1994 France, 1998 Eight European
countries, 1999
Patient group Non-
institutionalized
patients with
diabetes
Patients with
diabetes
Incident patients
with type 2 
diabetes
Patients with
diabetes
Patients with 
type 2 diabetes
Patients with 
type 2 diabetes
Top-down or
bottom-up
Bottom-up Bottom-up Bottom-up Top-down Review Bottom-up
Costs 
measured or 
assessed
Total direct
healthcare costs 
of persons with
diabetes
Costs of diabetes
and attributable
complication 
costs
Total direct
healthcare costs 
of persons with
diabetes
Costs of diabetes
and complication
costs
Total direct
healthcare costs 
of persons with
diabetes
Total direct
healthcare costs 
of persons with
diabetes
Source and
method of cost
measurement
Survey data Diagnostic
category data,
application of
attributable risk
procedures
HMO electronic
medical record 
data
Administrative
databases
Published 
materials
Medical records,
patient
questionnaires
Control group Yes Not applicable Yes Not applicable Yes No
Cost estimate (Excess) costs 
of persons with
diabetes
Costs of diabetes
and its
complications
(Excess) costs 
of persons with
type 2 diabetes,
first 8 years from
diagnosis
Costs of diabetes
and its
complications
Excess costs of
persons with 
type 2 diabetes
(Total direct)
costs of persons
with diabetes
Direct medical
costs per 
person-year
Excess 
US-$ 6,889 = 
€ 7,769a 
US-$ 2,600 = 
€ 2,923a 
US-$ 2,257 = 
€ 2,545
SEK 18,600 = 
€ 2,165a 
FF 10,000 = 
€ 1,524a 
€ 2,834
a: Direct medical costs per person-year calculated from the reference paper. Exchange rates: US-$ 1 = € 1.12780, SEK 1 = € 0.11640, 1 FF = € 0.15240
(11.12.2000).
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The characteristics of some important reference studies on the
cost of diabetes are summarized in table 6. US studies tend to
report higher costs than European studies.4,5,15,33 This can in
part be explained by differential characteristics of the US and
European healthcare and accounting systems, by methodological
differences, and by the way of presentation. The American
Diabetes Association (ADA) reported US costs attributable to
type 1 and type 2 diabetes in 1997 of US-$ 98.2 billion.5 As in
our case, costs were calculated on the basis of a ‘bottom-up’
approach and of attributable risk procedures, but the assessment
of resource utilisation was more comprehensive.15 Reported
direct medical costs of $ 44.1 billion equal 4.5% of the total US
healthcare expenditures in 1997, comprising the costs of diabetes
itself and its chronic complications, as well as the costs of an
excess prevalence of general medical conditions observed in
diabetes patients, which we didn’t measure. Thus, the figure to
directly compare our results with is US-$ 19.5 billion only,
corresponding to US-$ 2600 per patient with diabetes (according
to the prevalence estimate of 3% used in the ADA study), and
to 2% of the total 1997 US healthcare expenditures. Obviously
these results are well in the same range as ours, especially in
relative terms and regarding the fact that the presumably higher
costs of type 1 diabetes are included here.
Another frequently cited study is the one by Rubin et al., which
estimated that persons with type 1 or type 2 diabetes accounted
for 14.6% of total US healthcare expenditures in 1992.4 This
figure refers to the total healthcare expenditures caused by
persons with diabetes, and not to diabetes-related costs only.
Also, it is based on a prevalence estimate of 4.5% which is
derived from broad inclusion criteria on the basis of self-
reporting. With these facts in mind the difference between the
results of Rubin and colleagues and our own estimates looses its
out-of-range quality.
Brown et al. conducted an analysis of electronic HMO patient
records, assessing the costs of patients with type 2 diabetes during
the first eight years after diagnosis.34 They reported yearly excess
costs of US-$ 2,257 (€ 2,545) compared to matched nondiabetic
patients. Their variation over the period observed was small.
Only few single-country cost of illness studies of diabetes have
been performed in Europe. Two studies conducted in the UK and
Sweden both used a ‘top down approach’ relying on public
registries.30,35 The latter reported 1994 costs of about SEK 18,600
(€ 2,000) per person-year. A 1998 French review yielded excess
costs of persons with type 2 diabetes of FF 10,000 (€ 1,524).36
The Costs of Diabetes in Europe – Type 2 (CODE-2) study was
conducted in eight European countries and, similar to Rubin et
al., measured direct healthcare expenditures for people with
diabetes instead of diabetes-related expenditures only.28
Thus, somewhat higher cost results than ours are expected. In
fact, CODE-2 calculated mean direct per capita healthcare
expenditures of € 2,834 per person-year.28
Overall, the results reported in the international literature
correspond well with our corrected estimate of CHF 3,324
(€ 2,201).
Our findings that in-patient costs account for the largest single
share of direct medical expenditures related to diabetes and that
complication status strongly influences per capita costs is con-
firmed by virtually all international studies.4,5,15,33,37
The results from CODE-2 are in line with many of our more
detailed observations. They confirm that the presence of com-
plications is responsible for an impressing increase in per capita
costs.28,38 This is particularly true if macro- and microvascular
complications are present at the same time.29 In CODE-2 as in
our study, hospitalizations are the most important single factor
contributing to the direct costs of type 2 diabetes.28 They
represent a share of 30–65% of the total direct costs in the
CODE-2 countries, compared to 52.9% in Switzerland. Oral
antidiabetic drugs account for a proportion of 2–7% in CODE-2
and for 7.4% in the study presented here. Our observation of a
dependence of direct costs on treatment type is also mirrored in
CODE-2.38
The observation that the costs of diet-treated patients and of
patients treated with oral antidiabetic drugs were nearly identical
results from distinctly higher inpatient costs in the former group.
The difference observed, though, is far from statistical signi-
ficance (p=0.55). An artefact may be the most likely explana-
tion. Both groups were similar in many respects, and no con-
clusive differences favouring the drug-treated group were seen in
the number of hospitalisations or the share of complications and
revascularization procedures. Outliers were neither playing an
important role.
In Switzerland, as in other countries, type 2 diabetes is a disease
which not only has an important medical but also an enormous
economic impact. It is a challenge for the Swiss as well as any
other healthcare system to allocate resources for the prevention
of type 2 diabetes and its complications instead of simply accept-
ing very high treatment costs for these conditions. Our results
confirm this despite their conservative nature. Future studies will
have to refine our assessment of direct and especially indirect
costs, to get the full picture into view.
This study was supported by an unrestricted, educational grant from
Novartis, Switzerland.
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